RecruitingNot ApplicableNCT05766254

Identify the Optimal TMS Target to Modulate Reward Activity

Identify the Optimal TMS Target to Modulate Midcingulate Reward Activity in Smokers


Sponsor

Rutgers, The State University of New Jersey

Enrollment

36 participants

Start Date

Mar 24, 2023

Study Type

INTERVENTIONAL

Conditions

Summary

Our primary goal will be to identify the optimal prefrontal-cingulate target by systematically measuring the efficacy of various image-based targeting techniques to increase the reward positivity using the 10-Hz TMS protocol in dependent smokers. Our secondary objective will be to measure the targets' effectiveness to increase decision-making capacity using the probabilistic selection task (PST). Our third objective will be to specifically assess whether the TMS targets has a differential impact on state levels of craving relative to baseline (Tobacco Craving Questionnaire \[TCQ\]. We plan to accomplish these three objectives using a randomized, controlled experiment involving 3 sessions.


Eligibility

Min Age: 18 YearsMax Age: 55 Years

Plain Language Summary

Simplified for easier understanding

This study uses brain imaging (fMRI) and brain stimulation (repetitive TMS) to identify the best brain target for reducing the overactive reward-seeking behavior that drives nicotine addiction. The brain's reward system is central to addiction — nicotine hijacks it, making smoking feel rewarding and making it hard to stop. By identifying which brain region, when stimulated, most effectively dampens this reward response, researchers hope to optimize non-invasive brain stimulation as a smoking cessation tool. Nicotine-dependent adults aged 18 to 55 who are in stable mental and physical health are eligible. Participants must not have had substance abuse treatment in the past 30 days and, if female, must not be pregnant. Those with contraindications to MRI (such as metal implants or claustrophobia) or TMS (seizure history, brain injury, certain implants), brain lesions on MRI, or a history of major psychiatric disorders including bipolar disorder, schizophrenia, PTSD, or dementia are excluded. Smoking kills millions of people each year, and many smokers are unable to quit despite using available pharmacological treatments. Non-invasive brain stimulation has shown promise as an addiction treatment, but its effectiveness has been limited by uncertainty about the optimal target. This study could identify the precise brain circuit to target — a key step toward developing more powerful, personalized cessation interventions.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DEVICEActive 10-Hz TMS to the DLPFC

The active group will receive 10hz TMS stimulation. Participants in the active stimulation group will receive10-Hz TMS to left DLPFC. The LDLPFC will be based on 4 targeting neuroimaging methods (cortical thickness, fMRI, diffusion imaging, functional connectivity). TMS will be delivered using a robotic neuronavigation system (Smartmove, ANT). Stimulation intensity will be standardized at 110% of RMT and adjusted to the skull to cortical surface based on e-field calculations (simnibs). Stimulation will be delivered to the L-DLPFC using a active/placebo figure-8 coil and a magventure TMS device.

DEVICESham TMS-DLPFC

The parameters in the active arms will be as above with the internal randomization of the device internally switching to sham in a blinded fashion.


Locations(1)

Rutgers University - Newark

Newark, New Jersey, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05766254


Related Trials